MEI Pharma (NASDAQ: MEIP) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare MEI Pharma to similar businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.
This table compares MEI Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|MEI Pharma Competitors||-5,441.68%||-162.70%||-35.92%|
MEI Pharma has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, MEI Pharma’s rivals have a beta of 2.42, indicating that their average stock price is 142% more volatile than the S&P 500.
This is a summary of current ratings for MEI Pharma and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|MEI Pharma Competitors||925||3348||11860||238||2.70|
MEI Pharma currently has a consensus target price of $6.75, suggesting a potential upside of 209.63%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.52%. Given MEI Pharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe MEI Pharma is more favorable than its rivals.
Institutional and Insider Ownership
23.2% of MEI Pharma shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.3% of MEI Pharma shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares MEI Pharma and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MEI Pharma||$23.25 million||$2.67 million||-43.60|
|MEI Pharma Competitors||$290.27 million||$35.99 million||54.46|
MEI Pharma’s rivals have higher revenue and earnings than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
MEI Pharma rivals beat MEI Pharma on 7 of the 13 factors compared.
About MEI Pharma
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.